IBI306 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
79家族性高コレステロール血症(ホモ接合体)2

79. 家族性高コレステロール血症(ホモ接合体)


臨床試験数 : 145 薬物数 : 114 - (DrugBank : 26) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 17
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04948008
(ClinicalTrials.gov)
November 5, 201929/6/2021Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial HypercholesterolemiaA Seamless Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia in ChinaFamilial Hypercholesterolemia - Homozygous;Lipid Metabolism Disorders;Proprotein Convertase Subtilisin/Kexin 9Biological: IBI306Shenzhen People's HospitalNULLRecruiting18 Years80 YearsAll8Phase 2/Phase 3China
2NCT04031742
(ClinicalTrials.gov)
September 29, 201922/7/2019A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial HypercholesterolemiaPhase 2b/3 Study to Assess the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia.Homozygous Familial HypercholesterolemiaBiological: IBI306Innovent Biologics (Suzhou) Co. Ltd.NULLActive, not recruiting18 Years80 YearsAll30Phase 2/Phase 3China